Sadaharu Iio

Nishinomiya-hama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Journal: PloS one

Published: January 29, 2026

Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis.

Impact of Treatment Response to Anticoagulant Therapy on Liver-Related Events in Patients With Cirrhosis and Portal Vein Thrombosis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 18, 2025

Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.

Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.

Journal: Journal of gastroenterology

Published: July 29, 2025

Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Journal: Journal of gastroenterology and hepatology

Published: March 24, 2025

Improvement of hepatic reserve and changes in liver and spleen volume after balloon-occluded retrograde transvenous obliteration.

Improvement of hepatic reserve and changes in liver and spleen volume after balloon-occluded retrograde transvenous obliteration.

Journal: BMC gastroenterology

Published: May 21, 2024

Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.

Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.

Journal: PloS one

Published: August 10, 2023

Efficacy and associated factors of endoscopic transpapillary drainage for postoperative biliary leakage.

Efficacy and associated factors of endoscopic transpapillary drainage for postoperative biliary leakage.

Journal: DEN open

Published: May 02, 2023

Neuroendocrine tumor of the minor duodenal papilla with lymph node metastasis: a case report and literature review.

Neuroendocrine tumor of the minor duodenal papilla with lymph node metastasis: a case report and literature review.

Journal: International cancer conference journal

Published: March 07, 2023

IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification.

IgE Plasma Cell Leukemia Harboring t(11;14) and 1q Amplification.

Journal: Case reports in hematology

Published: November 16, 2022

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Journal: PloS one

Published: September 06, 2022

Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.

Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: September 01, 2022

Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.

Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 06, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026